HGH Fragment 176-191 + CJC-1295 + Ipamorelin blend

Last Updated: August 2026

This stack combines two different kinds of compound: the HGH Fragment 176-191 (a lipolytic fragment of growth hormone studied for fat metabolism) with a GH secretagogue base — CJC-1295 (without DAC) plus the selective Ipamorelin. It is research-use-only, not an approved product, and WADA-prohibited. None of the three has a lawful pharmacy-compounding pathway. The FDA's Pharmacy Compounding Advisory Committee recommended against adding CJC-1295 to the 503A bulk-substances list ("do not include") in December 2024 and, at that same December 4, 2024 meeting, voted against AOD-9604; neither the native HGH Fragment 176–191 nor AOD-9604 is on the 503A list. Ipamorelin acetate is on the FDA's active Category 2 bulk-substances list under the 503B outsourcing-facility route, not Category 1. In sport, all three are prohibited at all times by the World Anti-Doping Agency: the growth-hormone fragment (and AOD-9604) under Section S2.2.3 (GH fragments), and CJC-1295 and ipamorelin under Section S2.2.4 (growth-hormone-releasing factors and secretagogues). The combination is not an approved product and is research-use-only

Why combine a GH fragment with a secretagogue pair?

The logic is to pair two distinct angles: HGH Fragment 176-191 is studied specifically for its lipolytic (fat-breakdown) effect and — importantly — is not a secretagogue and doesn't meaningfully raise GH or IGF-1, while CJC-1295 + Ipamorelin provide the GHRH+GHRP synergy that stimulates the body's own GH pulse; combined, the stack aims to pair a targeted fat-loss fragment with GH stimulation. No controlled clinical trial of this three-peptide combination has been published as of August 2026. The rationale — a lipolytic GH fragment alongside a GHRH analog and a ghrelin-mimetic secretagogue — is mechanistic, and the fragment component carries no human trial of its own, so the blend has no clinical-outcome evidence behind it. One caution on the fragment's evidence: HGH Fragment 176–191 itself has no published human clinical trial. The human record often attached to "fragment 176–191" actually belongs to its modified analog, AOD-9604 (Tyr-hGH177–191) — a separately catalogued compound that ran six placebo-controlled trials (about 893 participants) and was well tolerated, but was discontinued in 2007 after its 24-week Phase 2b obesity trial missed its primary weight-loss endpoint. The two are not interchangeable, and results or citations for AOD-9604 do not transfer to the native fragment. AOD-9604 hgh-fragment-176-191-science-fat-loss This is a mechanistic rationale, not a clinically-validated combined outcome.

What's the status, and how does Peptigrity verify?

The combination is not an approved product and is research-use-only; verify each labeled component's identity and purity via HPLC and mass-spec. Peptigrity collects independent third-party Certificates of Analysis for the HGH Fragment 176–191 + CJC-1295 + Ipamorelin blend from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate; the trust score weights lab purity and reviews equally (50/50). See how to read lab results.

Educational information only; not medical advice. This is a research-use-only stack, not an approved therapy. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.